Published in BMC Health Serv Res on April 03, 2015
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Review of statistical methods for analysing healthcare resources and costs. Health Econ (2010) 2.27
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ (2008) 1.64
Determinants of HIV outpatient service utilization: a systematic review. AIDS Behav (2015) 1.48
Collecting unit cost data in multicentre studies. Creating comparable methods. Eur J Health Econ (2005) 1.46
The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41
Behavioral and clinical characteristics of persons receiving medical care for HIV infection - Medical Monitoring Project, United States, 2009. MMWR Surveill Summ (2014) 1.36
The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS (2004) 1.27
The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr (2011) 1.24
New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res (2012) 1.09
Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res (2002) 1.07
The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res (2009) 1.00
Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother (2004) 1.00
The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy (2008) 0.92
Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018. J Int AIDS Soc (2014) 0.90
Counting the cost of not costing HIV health facilities accurately: pay now, or pay more later. Pharmacoeconomics (2012) 0.89
Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econ (2012) 0.87
The cost of universal screening for gestational diabetes mellitus in Ireland. Diabet Med (2011) 0.86
Increased costs of HIV care associated with aging in an HIV-infected population. HIV Med (2014) 0.86
HIV treatment outcomes in Europe and North America: what can we learn from the differences? Expert Rev Anti Infect Ther (2014) 0.80
Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden. Pharmacoeconomics (2010) 0.78